NCT00113282View on ClinicalTrials.gov

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

PHASE2CompletedINTERVENTIONAL

Enrollment

57

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

February 29, 2008

Conditions

HIV Infections

Interventions

DRUG

Interleukin-2 (IL-2)

Trial Locations (1)

75015

Hôpital Necker service des Maladies Infectieuses, Paris

Sponsors

Collaborators (1)

Chiron Corporation

All Listed Sponsors

collaborator

Chiron Corporation

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV